Chaperonin 10: Phase II data

Invion reported data from a double-blind, placebo-controlled, U.S. Phase II trial in 28 patients with SLE evaluating twice-weekly 10, 30 and 100 mg doses of IV INV103. Invion said “serum biomarkers of...